GILD241122C83000
- 15.45
- 0.000.00%
Gilead Sciences Newsroom
Gilead Sciences Ticks Upward for the Eight Consecutive Session
Benign Growth For Gilead Sciences, Inc. (NASDAQ:GILD) Underpins Its Share Price
Express News | Gilead : Jefferies Raises Target Price to $115 From $105
Gilead Sciences(GILD.US) Officer Sells US$15.09 Million in Common Stock
$Gilead Sciences(GILD.US)$ Officer Parsey Merdad sold 164.21K shares of common stock on Nov 27, 2024 at an average price of $91.9184 for a total value of $15.09 million.Source: Announcement What is
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here Is What You Need to Know
RBC Capital Sticks to Their Hold Rating for Gilead Sciences (GILD)
Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results
Express News | Gilead Announces New England Journal of Medicine Publication of Purpose 2 Results
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Gilead Acquires Investigational HIV Vaccine From Spanish Biotech Aelix
Price Over Earnings Overview: Gilead Sciences
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
The Children's Inn at NIH Announces $1 Million Grant From Gilead Sciences, Inc.
Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics
3 'Buy' Stocks and 2 'Hold' Stocks According to Oppenheimer
Express News | ubs group has raised the target price of gilead sciences from $70.00 to $96.00.
Gilead Sciences Price Target Raised to $96.00/Share From $70.00 by UBS
Optimism Over Global Healthcare Sector Rises: Jefferies
UBS Initiates Gilead Sciences(GILD.US) With Hold Rating, Announces Target Price $96
Gilead Sciences Is Maintained at Outperform by Mizuho